Mohamad Mohty , MD, PhD1,2 and Florent Malard , MD, PhD1,2
doi : 10.1200/JCO.21.00622
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 1951-1954
Allison J. Applebaum , PhD1,2; Erin E. Kent , PhD3,4; and Wendy G. Lichtenthal , PhD1,2
doi : 10.1200/JCO.21.00402
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 1955-1958
Martin Hutchings , PhD1; Franck Morschhauser, MD, PhD2; Gloria Iacoboni , MD3,4; Carmelo Carlo-Stella , MD5; Fritz C. Offner, MD, PhD6; Anna Sureda , MD, PhD7; Gilles Salles , MD8; Joaqu?n Mart?nez-Lopez, MD, PhD, MBA9; Michael Crump, MD10; Denise N. Thomas, MSc11; Peter N. Morcos, PharmD11; Cristiano Ferlini, MD11; Ann-Marie E. Br?ske, PhD12; Anton Belousov, PhD13; Marina Bacac, PhD13; Natalie Dimier, PhD14; David J. Carlile, PhD14; Linda Lundberg, PhD15; David Perez-Callejo, MD, PhD15; Pablo Uma?a, PhD13; Tom Moore, MD12; Martin Weisser, MD12; and Michael J. Dickinson , MBBS, DMedSci16
doi : 10.1200/JCO.20.03175
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 1959-1970
Glofitamab is a T-cell–engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (Gpt) to reduce toxicity, are presented.
Bronwen E. Shaw, MD, PhD1; Antonio Martin Jimenez-Jimenez, MD, MS2; Linda J. Burns, MD1; Brent R. Logan, PhD1; Farhad Khimani, MD3; Brian C. Shaffer, MD4; Nirav N. Shah, MD5; Alisha Mussetter, BS6; Xiao-Ying Tang, MPH1; John M. McCarty, MD7; Asif Alavi, MD8; Nosha Farhadfar, MD9; Katarzyna Jamieson, MD10; Nancy M. Hardy, MD11; Hannah Choe, MD12; Richard F. Ambinder, MD, PhD13; Claudio Anasetti, MD3; Miguel-Angel Perales, MD4; Stephen R. Spellman, MBS6; Alan Howard, PhD6; Krishna V. Komanduri, MD2; Leo Luznik, MD13; Maxim Norkin, MD, PhD14; Joseph A. Pidala, MD, PhD3; Voravit Ratanatharathorn, MD8; Dennis L. Confer, MD6; Steven M. Devine, MD6; Mary M. Horowitz, MD, MS1; and Javier Bola?os-Meade, MD13
doi : 10.1200/JCO.20.03502
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 1971-1982
Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.
Pauline Dürr1,2; Katja Schlichtig2,3; Carolin Kelz2,3; Birgit Deutsch, MD2,3; Renke Maas, MD2,3; Michael J. Eckart, MD4; Jochen Wilke, MD5; Harald Wagner, MD5; Kerstin Wolff, MD2,6; Caroline Preu?, MD2,7; Valeska Brückl, MD2,8; Norbert Meidenbauer, MD2,8; Christian Staerk, PhD9; Andreas Mayr, PhD9; Rainer Fietkau, MD2,10; Peter J. Goebell, MD2,11; Frank Kunath, MD2,11; Matthias W. Beckmann, MD2,7; Andreas Mackensen , MD2,8; Markus F. Neurath, MD2,6; Marianne Pavel, MD2,6; Frank D?rje, PhD, MBA1,2; and Martin F. Fromm , MD2,3
doi : 10.1200/JCO.20.03088
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 1983-1994
Oral anticancer drugs (eg, kinase inhibitors) play an important role in cancer therapy. However, considerable challenges regarding medication safety of oral anticancer drugs have been reported. Randomized, controlled, multicenter studies on the impact of intensified clinical pharmacological/pharmaceutical care on patient safety and patient treatment perception are lacking.
Ben M. Eyck, MD1; J. Jan B. van Lanschot, MD, PhD1,2; Maarten C. C. M. Hulshof, MD, PhD3; Berend J. van der Wilk, MD1; Joel Shapiro, MD, PhD1; Pieter van Hagen, MD, PhD1; Mark I. van Berge Henegouwen, MD, PhD4; Bas P. L. Wijnhoven, MD, PhD1; Hanneke W. M. van Laarhoven, MD, PhD5; Grard A. P. Nieuwenhuijzen, MD, PhD6; Geke A. P. Hospers, MD, PhD7; Johannes J. Bonenkamp, MD, PhD8; Miguel A. Cuesta, MD, PhD9; Reinoud J. B. Blaisse, MD10; Olivier R. Busch, MD, PhD4; Geert-Jan M. Creemers, MD, PhD11; Cornelis J. A. Punt, MD, PhD12,13; John Th. M. Plukker, MD, PhD14; Henk M. W. Verheul, MD, PhD15,16; Ernst J. Spillenaar Bilgen, MD, PhD17; Maurice J. C. van der Sangen, MD, PhD18; Tom Rozema, MD19,20; Fiebo J. W. ten Kate, MD, PhD21; Jannet C. Beukema, MD22; Anna H. M. Piet, MD23; Caroline M. van Rij, MD24; Janny G. Reinders, MD25; Hugo W. Tilanus, MD, PhD26; Ewout W. Steyerberg, PhD27,28; and Ate van der Gaast, MD, PhD29; for the CROSS Study Group
doi : 10.1200/JCO.20.03614
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 1995-2004
Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer. We aimed to assess long-term outcome of this regimen.
Eva Maria Ciruelos, MD, PhD1; Hope S. Rugo , MD2; Ingrid A. Mayer , MD, MS3; Christelle Levy, MD4; Frédéric Forget, MD5; Juan Ignacio Delgado Mingorance, MD6; Tamar Safra , MD7; Norikazu Masuda , MD, PhD8; Yeon Hee Park, MD9; Dejan Juric , MD10; Pierfranco Conte , MD11; Mario Campone, MD, PhD12; Sibylle Loibl , MD13,14; Hiroji Iwata , MD15; Xiaolei Zhou, PhD16; Jinhee Park, PhD17; Antonia Ridolfi, MS18; Ines Lorenzo, PharmD19; and Fabrice André , MD, PhD20
doi : 10.1200/JCO.20.01139
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2005-2015
In the phase III SOLAR-1 trial (NCT02437318), the PI3K?-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. We assessed health-related quality of life using patient-reported outcome measures in these patients.
Volkan Turan, MD1,2; Matteo Lambertini, MD3,4; Dong-Yun Lee, MD5; Erica Wang, MD6; Florian Clatot, MD7; Beth Y. Karlan, MD8; Isabelle Demeestere, MD9; Heejung Bang, PhD10; and Kutluk Oktay, MD, PhD1,11
doi : 10.1200/JCO.20.02880
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2016-2024
To determine whether germline BRCA (gBRCA) pathogenic variants are associated with decreased ovarian reserve.
Yasuhisa Hasegawa, MD, PhD1; Kiyoaki Tsukahara, MD, PhD2; Seiichi Yoshimoto, MD, PhD3; Kouki Miura, MD, PhD4; Junkichi Yokoyama, MD, PhD5; Shigeru Hirano, MD, PhD6; Hirokazu Uemura, MD, PhD7; Masashi Sugasawa, MD, PhD8; Tomokazu Yoshizaki, MD, PhD9; Akihiro Homma, MD, PhD10; Kazuaki Chikamatsu, MD, PhD11; Mikio Suzuki, MD, PhD12; Akihiro Shiotani, MD, PhD13; Takashi Matsuzuka, MD, PhD1,14; Naoyuki Kohno, MD, PhD15; Masakazu Miyazaki, MD, PhD16; Isao Oze, MD, PhD17; Keitaro Matsuo, MD, PhD17; Shigeru Kosuda, MD, PhD18; and Yasushi Yatabe, MD, PhD3; for the HNCMM Research Group
doi : 10.1200/JCO.20.03637
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2025-2036
This study aimed to compare patients with early oral cavity squamous cell carcinoma (OCSCC) (tumor category [T] 1-2, node-negative, and no distant metastasis) treated with traditional elective neck dissection (ND) with those managed by sentinel lymph node biopsy (SLNB) using survival and neck function and complications as end points.
Jennifer J. Griggs , MD, MPH1; Kari Bohlke , ScD2; Edward P. Balaban, DO3; James J. Dignam, PhD4; Evan T. Hall , MD, MPhil5; R. Donald Harvey , PharmD6; Diane P. Hecht , PharmD, MEd7; Kelsey A. Klute, MD8; Vicki A. Morrison, MD9; T. May Pini , MD, MPH10; Gary L. Rosner , ScD11; Carolyn D. Runowicz , MD12; Michelle Shayne, MD13; Alex Sparreboom , PhD14; Sophia Turner, MSc15; Corrine Zarwan, MD16; and Gary H. Lyman , MD, MPH5
doi : 10.1200/JCO.21.00471
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2037-2048
To provide recommendations for appropriate dosing of systemic antineoplastic agents in obese adults with cancer.
Kartik Anand, MD and Joe Ensor , PhD
doi : 10.1200/JCO.21.00005
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2049-2050
Kei Kunimasa , MD, PhD
doi : 10.1200/JCO.21.00266
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2050-2051
Michael S. Ewer , MD, JD, PhD
doi : 10.1200/JCO.21.00502
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2051-2052
doi : 10.1200/JCO.21.01212
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2053-2053
doi : 10.1200/JCO.21.01191
Journal of Clinical Oncology 39, no. 18 (June 20, 2021) 2054-2054
Do you want to add Medilib to your home screen?